ADAR1 Capital Management LLC Grows Stake in Fulcrum Therapeutics, Inc. $FULC

Key Points

• ADAR1 Capital Management LLC increased its stake in Fulcrum Therapeutics by 150.0%, acquiring a total of 490,532 shares, which is valued at approximately $1.41 million.
• Fulcrum Therapeutics has received multiple analyst upgrades, with target prices ranging from $5.00 to $10.00, suggesting a positive outlook despite one downgrade to a "sell" rating.
• The company's stock is currently priced at $6.48, with a 12-month trading range between $2.32 and $9.30, and a market capitalization of $350.50 million.

ADAR1 Capital Management LLC increased its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 150.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 490,532 shares of the company's stock after buying an additional 294,284 shares during the period. ADAR1 Capital Management LLC owned 0.91% of Fulcrum Therapeutics worth $1,413,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Algert Global LLC increased its holdings in shares of Fulcrum Therapeutics by 6.0% in the first quarter. Algert Global LLC now owns 36,147 shares of the company's stock worth $104,000 after purchasing an additional 2,030 shares during the period. American Century Companies Inc. increased its holdings in shares of Fulcrum Therapeutics by 2.6% in the 1st quarter. American Century Companies Inc. now owns 123,711 shares of the company's stock worth $356,000 after buying an additional 3,100 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Fulcrum Therapeutics during the 4th quarter valued at $38,000. Brooklyn Investment Group lifted its holdings in shares of Fulcrum Therapeutics by 209.7% during the 1st quarter. Brooklyn Investment Group now owns 12,190 shares of the company's stock worth $35,000 after acquiring an additional 8,254 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in Fulcrum Therapeutics by 34.4% in the fourth quarter. Wells Fargo & Company MN now owns 34,264 shares of the company's stock worth $161,000 after acquiring an additional 8,761 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Price Performance

FULC traded up $0.78 during midday trading on Friday, reaching $7.66. 599,040 shares of the company's stock traded hands, compared to its average volume of 381,469. Fulcrum Therapeutics, Inc. has a 52 week low of $2.32 and a 52 week high of $9.30. The firm has a fifty day moving average of $7.06 and a two-hundred day moving average of $5.48. The stock has a market capitalization of $414.34 million, a price-to-earnings ratio of -6.28 and a beta of 2.82.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.01. Sell-side analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on FULC shares. HC Wainwright raised Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $4.00 to $12.00 in a research note on Tuesday, July 29th. Cantor Fitzgerald upgraded Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 target price for the company in a research report on Thursday, May 15th. Leerink Partnrs upgraded shares of Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Friday, May 23rd. Leerink Partners raised Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and lifted their price target for the stock from $4.00 to $12.00 in a research note on Friday, May 23rd. Finally, Royal Bank Of Canada increased their price objective on Fulcrum Therapeutics from $4.00 to $5.00 and gave the company a "sector perform" rating in a research note on Wednesday, July 30th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $7.57.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.